FLIBANSERIN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H21F3N4O
Molecular Weight	390.4021
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

FC(F)(F)C1=CC(=CC=C1)N2CCN(CCN3C(=O)NC4=C3C=CC=C4)CC2

InChI

InChIKey=PPRRDFIXUUSXRA-UHFFFAOYSA-N

InChI=1S/C20H21F3N4O/c21-20(22,23)15-4-3-5-16(14-15)26-11-8-25(9-12-26)10-13-27-18-7-2-1-6-17(18)24-19(27)28/h1-7,14H,8-13H2,(H,24,28)

HIDE SMILES / InChI

Molecular Formula	C20H21F3N4O
Molecular Weight	390.4021
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/12177684
Curator's Comment: Description was created based on several sources, including https://www.drugbank.ca/drugs/DB04908

Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder drug by Sprout Pharmaceuticals. Flibanserin's mechanism of action is attributed to its high affinity for 5-HTA1 and 5-HTA2 receptors, displaying agonist activity on 5-HTA1 and antagonist on 5-HTA2, resulting in lowering of serotonin in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters. Flibansetrin has high affinity for serotonin receptors in the brain: it acts as an agonist on 5-HT1A and an antagonist on 5-HT2A. In vivo, flibanserin binds equally to 5-HT1A and 5-HT2A receptors. However, under higher levels of brain 5-HT (i.e., under stress), flibanserin may occupy 5-HT2A receptors in higher proportion than 5-HT(1A) receptors. It may also moderately antagonize D4 (dopamine) receptors and 5-HT2B and 5-HTB2C. Its action on neurotransmitter receptors may contribute to reduction in serotonin levels and increase in dopamine and norepinephrine levels, all of which may play part in reward processing. Flibanserin is sold under the trade name Addyi and indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Dopamine D4 receptor 71 Target ID: CHEMBL219 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12177684 \| http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf \| https://www.drugbank.ca/drugs/DB04908	Antagonist 2778	7.31 null [pKi]
Serotonin 1a (5-HT1a) receptor 172 Target ID: CHEMBL214 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12177684 \| https://www.drugbank.ca/drugs/DB04908 \| http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf	Agonist 2678	4.0 nM [EC50]
Serotonin 2a (5-HT2a) receptor 231 Target ID: CHEMBL224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12177684 \| https://www.drugbank.ca/drugs/DB04908 \| http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf	Antagonist 2778	115.0 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypoactive sexual desire disorder 2 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25187905	Primary		Approved 8429	ADDYI Approved Use ADDYI is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to: •A co-existing medical or psychiatric condition, •Problems within the relationship, or •The effects of a medication or other drug substance. Acquired HSDD refers to HSDD that develops in a patient who previously had no problems with sexual desire. Generalized HSDD refers to HSDD that occurs regardless of the type of stimulation, situation or partner. Limitations of Use •ADDYI is not indicated for the treatment of HSDD in postmenopausal women or in men. •ADDYI is not indicated to enhance sexual performance. ADDYI is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to: •A co-existing medical or psychiatric condition, •Problems within the relationship, or •The effects of a medication or other drug substance. (1) Limitations of Use: •ADDYI is not indicated for the treatment of HSDD in postmenopausal women or in men. (1) •ADDYI is not indicated to enhance sexual performance. (1) Launch Date 2015

C_max

Value	Dose	Co-administered	Analyte	Population
419 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022526s009lbl.pdf	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		FLIBANSERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
1543 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022526s009lbl.pdf	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		FLIBANSERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
11 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022526s009lbl.pdf	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		FLIBANSERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
2% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022526s009lbl.pdf	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		FLIBANSERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
600 mg single, oral Dose: 600 mg Route: oral Route: single Dose: 600 mg Sources: https://pubmed.ncbi.nlm.nih.gov/28814122	unknown, 2 yeras n = 1 Health Status: unknown Age Group: 2 yeras Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/28814122	Other AEs: Seizures... Other AEs: Seizures (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/28814122
100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf	unhealthy, 36 years (range: 18-56 years) n = 1543 Health Status: unhealthy Condition: hypoactive sexual desire disorder Age Group: 36 years (range: 18-56 years) Sex: F Population Size: 1543 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf	Disc. AE: Dizziness, Nausea... AEs leading to discontinuation/dose reduction: Dizziness (1.7%) Nausea (1.2%) Insomnia (1.1%) Somnolence (1.1%) Anxiety (1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf
250 mg 1 times / day steady, oral MTD Dose: 250 mg, 1 times / day Route: oral Route: steady Dose: 250 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000MedR.pdf Page: p. 127	unhealthy n = 6 Health Status: unhealthy Sex: F Population Size: 6 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000MedR.pdf Page: p. 127	Other AEs: Dizziness, Nausea... Other AEs: Dizziness (83%) Nausea (67%) Somnolence (83%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000MedR.pdf Page: p. 127
100 mg 1 times / day multiple, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Co-administed with:: alcohol(0.4 g/kg) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf	unhealthy n = 25 Health Status: unhealthy Sex: M+F Population Size: 25 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf	Other AEs: Hypotension, Syncope... Other AEs: Hypotension (severe) Syncope Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf
20 mg single, intravenous Dose: 20 mg Route: intravenous Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/22219166	healthy n = 12 Health Status: healthy Sex: M Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/22219166	Sources: https://pubmed.ncbi.nlm.nih.gov/22219166

AEs

AE	Significance	Dose	Population
Seizures	1 patient	600 mg single, oral Dose: 600 mg Route: oral Route: single Dose: 600 mg Sources: https://pubmed.ncbi.nlm.nih.gov/28814122	unknown, 2 yeras n = 1 Health Status: unknown Age Group: 2 yeras Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/28814122
Anxiety	1% Disc. AE	100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf	unhealthy, 36 years (range: 18-56 years) n = 1543 Health Status: unhealthy Condition: hypoactive sexual desire disorder Age Group: 36 years (range: 18-56 years) Sex: F Population Size: 1543 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf
Insomnia	1.1% Disc. AE	100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf	unhealthy, 36 years (range: 18-56 years) n = 1543 Health Status: unhealthy Condition: hypoactive sexual desire disorder Age Group: 36 years (range: 18-56 years) Sex: F Population Size: 1543 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf
Somnolence	1.1% Disc. AE	100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf	unhealthy, 36 years (range: 18-56 years) n = 1543 Health Status: unhealthy Condition: hypoactive sexual desire disorder Age Group: 36 years (range: 18-56 years) Sex: F Population Size: 1543 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf
Nausea	1.2% Disc. AE	100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf	unhealthy, 36 years (range: 18-56 years) n = 1543 Health Status: unhealthy Condition: hypoactive sexual desire disorder Age Group: 36 years (range: 18-56 years) Sex: F Population Size: 1543 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf
Dizziness	1.7% Disc. AE	100 mg 1 times / day steady, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: steady Dose: 100 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf	unhealthy, 36 years (range: 18-56 years) n = 1543 Health Status: unhealthy Condition: hypoactive sexual desire disorder Age Group: 36 years (range: 18-56 years) Sex: F Population Size: 1543 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf
Nausea	67%	250 mg 1 times / day steady, oral MTD Dose: 250 mg, 1 times / day Route: oral Route: steady Dose: 250 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000MedR.pdf Page: p. 127	unhealthy n = 6 Health Status: unhealthy Sex: F Population Size: 6 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000MedR.pdf Page: p. 127
Dizziness	83%	250 mg 1 times / day steady, oral MTD Dose: 250 mg, 1 times / day Route: oral Route: steady Dose: 250 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000MedR.pdf Page: p. 127	unhealthy n = 6 Health Status: unhealthy Sex: F Population Size: 6 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000MedR.pdf Page: p. 127
Somnolence	83%	250 mg 1 times / day steady, oral MTD Dose: 250 mg, 1 times / day Route: oral Route: steady Dose: 250 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000MedR.pdf Page: p. 127	unhealthy n = 6 Health Status: unhealthy Sex: F Population Size: 6 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000MedR.pdf Page: p. 127
Syncope		100 mg 1 times / day multiple, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Co-administed with:: alcohol(0.4 g/kg) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf	unhealthy n = 25 Health Status: unhealthy Sex: M+F Population Size: 25 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf
Hypotension	severe	100 mg 1 times / day multiple, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Co-administed with:: alcohol(0.4 g/kg) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf	unhealthy n = 25 Health Status: unhealthy Sex: M+F Population Size: 25 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737 inhibitor 1587	substrate 1037	substrate 1217 inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2B6 810 P-gp 1461	CYP2C19 991 CYP1A2 1054 CYP2B6 664 CYP2C8 693 P-gp 1537 UGT 192 sulfotransferases 38

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000ClinPharmR.pdf#page=254 Page: 254.0	no
CYP2B6 1001	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000ClinPharmR.pdf#page=187 Page: 187.0	yes [Ki 6.4 uM]
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000ClinPharmR.pdf#page=187 Page: 187.0	yes [Ki 7.5 uM]
P-gp 1650	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000ClinPharmR.pdf#page=71 Page: 71.0	yes	yes (co-administration study) Comment: Digoxin exposure increased by 46%, 62% and 96% for Cmax, AUC0-t, and AUC0-inf, respectively, following multiple doses of flibanserin 100 mg co-administered with a single dose of digoxin 0.5 mg. A 96% increase in digoxin AUC suggests flibanserin is a P-gp inhibitor. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000ClinPharmR.pdf#page=71 Page: 71.0

Drug as victim

Target	Modality	Activity	Clinical evidence
P-gp 1537	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000ClinPharmR.pdf#page=117 Page: 117.0	likely
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000ClinPharmR.pdf#page=44 Page: 44.0	major	yes (co-administration study) Comment: In a pharmacokinetic drug interaction study of 50 mg flibanserin and 400 mg ketoconazole, a strong CYP3A4 inhibitor, syncope occurred in 1/24 (4%) healthy subjects treated with concomitant flibanserin and ketoconazole, 1/24 (4%) receiving flibanserin alone, and no subjects receiving ketoconazole alone. In this study, the concomitant use of flibanserin and ketoconazole increased flibanserin exposure 4.5-fold Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000ClinPharmR.pdf#page=44 Page: 44.0
CYP1A2 1054	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000ClinPharmR.pdf#page=44 Page: 44.0	poor
CYP2B6 664	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000ClinPharmR.pdf#page=44 Page: 44.0	poor
CYP2C8 693	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000ClinPharmR.pdf#page=44 Page: 44.0	poor
CYP2C9 1037	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000ClinPharmR.pdf#page=44 Page: 44.0	poor	no (co-administration study) Comment: A study comparing flibanserin exposure in CYP2C9 poor metabolizers to CYP2C9 extensive metabolizers was conducted in lieu of a drug interaction study with ADDYI and a strong CYP2C9 inhibitor. In 8 women who were poor metabolizers of CYP2C9, Cmax and AUC0-inf of flibanserin 100 mg once daily decreased 23% and 18%, compared to exposures among 8 extensive metabolizers of CYP2C9. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000ClinPharmR.pdf#page=44 Page: 44.0
CYP2D6 1217	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000ClinPharmR.pdf#page=44 Page: 44.0	poor	no (co-administration study) Comment: Paroxetine is a strong CYP2D6 inhibitor. In a study of 19 healthy male and female subjects, flibanserin exposure decreased by approximately 4% when flibanserin 50 mg twice daily was given with paroxetine compared to flibanserin alone. Paroxetine was dosed at 20 mg once daily for 3 days followed by 40 mg once daily for 7 days. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000ClinPharmR.pdf#page=44 Page: 44.0
UGT 192	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000ClinPharmR.pdf#page=167 Page: 167.0	yes
sulfotransferases 38	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000ClinPharmR.pdf#page=167 Page: 167.0	yes
CYP2C19 991	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000ClinPharmR.pdf#page=44 Page: 44.0	yes	yes (pharmacogenomic study) Comment: In a pharmacogenomic study of 100 mg ADDYI in subjects who were poor or extensive CYP2C19 metabolizers, syncope occurred in 1/9 (11%) subjects who were CYP2C19 poor metabolizers (this subject had a 3.2 fold higher flibanserin exposure compared to CYP2C19 extensive metabolizers) compared to no such adverse reactions in subjects who were CYP2C19 extensive metabolizers Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000ClinPharmR.pdf#page=44 Page: 44.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000PharmR.pdf#page=231 Page: 231.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:90865	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:90865
ChemicalBook	CB91178756	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB91178756
MolPort	MolPort-006-170-023	https://www.molport.com/shop/molecule-link/MolPort-006-170-023
ZINC	ZINC000052716421	http://zinc15.docking.org/substances/ZINC000052716421
eMolecules	36367115	https://www.emolecules.com/cgi-bin/more?vid=36367115

PubMed

Title	Date	PubMed
Anti-anhedonic actions of the novel serotonergic agent flibanserin, a potential rapidly-acting antidepressant.	1997 Dec 11	9537806
Lack of interaction between flibanserin and antidepressants in inducing serotonergic syndrome in rats.	2001 Mar	11343624
Region-dependent effects of flibanserin and buspirone on adenylyl cyclase activity in the human brain.	2002 Jun	12135537
Pharmacology of flibanserin.	2002 Summer	12177684
Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT(1A) receptors.	2003 Aug	12890707
Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response.	2004 Dec	15447813
Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine.	2004 Jan	14980000
Redistribution of the water channel protein aquaporin-4 and the K+ channel protein Kir4.1 differs in low- and high-grade human brain tumors.	2005 Apr	15723236
Agonist and antagonist properties of antipsychotics at human dopamine D4.4 receptors: G-protein activation and K+ channel modulation in transfected cells.	2008 May	17897483
Gateways to clinical trials.	2009 May	19557204
A new strategy for antidepressant prescription.	2010	21151361
Modifying 5-HT1A Receptor Gene Expression as a New Target for Antidepressant Therapy.	2010	20661455
Dysfunctional women remain unsexed.	2010 Aug	20653655
Management of hypoactive sexual desire disorder in women: current and emerging therapies.	2010 Aug 9	21072309
[Normality of the female libido? (2)].	2010 Jul 14	20701022
Drug for low sexual desire carries significant harms, FDA advisers find.	2010 Jul 7	20610515
Flibanserin, a drug intended for treatment of hypoactive sexual desire disorder in pre-menopausal women, affects spontaneous motor activity and brain neurochemistry in female rats.	2010 Jun	20422156
Involvement of serotonin receptor subtypes in the antidepressant-like effect of TRIM in the rat forced swimming test.	2010 May	20171242
Acute and repeated flibanserin administration in female rats modulates monoamines differentially across brain areas: a microdialysis study.	2010 May	20163532
FDA advisers to assess drug for low sexual desire in women.	2010 May 25	20501573
Consultation corner. The latest on female sexual health.	2010 Nov	21066837
Flibanserin: initial evidence of efficacy on sexual dysfunction, in patients with major depressive disorder.	2010 Oct	20646181
Do drugs have a role in turning indifference into passion?	2010 Oct 5	20923834
Flibanserin: a potential treatment for Hypoactive Sexual Desire Disorder in premenopausal women.	2010 Sep	20887163
Predicting in vivo absorption behavior of oral modified release dosage forms containing pH-dependent poorly soluble drugs using a novel pH-adjusted biphasic in vitro dissolution test.	2010 Sep	20472059
[When women complain about lacking libido. The problem with the desire].	2010 Sep 2	20923016
Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder.	2015 Feb	25659981
Flibanserin: First Global Approval.	2015 Oct	26412054

Patents

Sample Use Guides

In Vivo Use Guide

Recommended dosage is 100 mg taken once daily at bedtime, discontinue treatment after 8 weeks if no improvement

Route of Administration: Oral

In Vitro Use Guide

The concentration that reduces forskolin-induced cAMP formation by 50% in human hippocampus tissue was 4 nM.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:39:13 GMT 2023` Edited by `admin` on `Fri Dec 15 15:39:13 GMT 2023`
Record UNII	37JK4STR6Z
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FLIBANSERIN

Official Name

English

1,3-DIHYDRO-1-(2-(4-(3-(TRIFLUOROMETHYL)PHENYL)-1-PIPERAZINYL)ETHYL)-2H-BENZIMIDAZOL-2-ONE

Systematic Name

English

BIMT 17 BS

Code

English

1-(2-(4-(.ALPHA.,.ALPHA.,.ALPHA.-TRIFLUORO-M-TOLYL)-1-PIPERAZINYL)ETHYL)-2-BENZIMIDAZOLINONE

Systematic Name

English

BIMT-17-BS

Code

English

BIMT 17

Code

English

ADDYI

Brand Name

English

flibanserin [INN]

Common Name

English

FLIBANSERIN [MART.]

Common Name

English

Flibanserin [WHO-DD]

Common Name

English

FLIBANSERIN [USAN]

Common Name

English

BIMT-17

Code

English

FLIBANSERIN [ORANGE BOOK]

Common Name

English

ECTRIS

Brand Name

English

FLIBANSERIN [MI]

Common Name

English

Classification Tree Code System Code

WHO-ATC

G02CX02